heterogeneity; implication; molecular level; thyroid cancer; tumor ecosystem; Oncology; Cancer Research
Abstract :
[en] Though heterogeneity of cancers is recognized and has been much discussed in recent years, the concept often remains overlooked in different routine examinations. Indeed, in clinical or biological articles, reviews, and textbooks, cancers and cancer cells are generally presented as evolving distinct entities rather than as an independent heterogeneous cooperative cell population with its self-oriented biology. There are, therefore, conceptual gaps which can mislead the interpretations/diagnostic and therapeutic approaches. In this short review, we wish to summarize and discuss various aspects of this dynamic evolving heterogeneity and its biological, pathological, clinical, diagnostic, and therapeutic implications, using thyroid carcinoma as an illustrative example.
Disciplines :
Genetics & genetic processes
Author, co-author :
JACQUEMIN, VALERIE ; Centre Hospitalier Universitaire de Liège - CHU > > Service de génétique ; Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
Antoine, Mathieu ; Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
Dom, Geneviève; Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
Detours, Vincent; Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
Maenhaut, Carine; Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
Dumont, Jacques E; Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire (IRIBHM), Université Libre de Bruxelles, 1070 Brussels, Belgium
Language :
English
Title :
Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications.
Metabolically, PTC exhibit a reverse Warburg phenotype with mitochondrial activity, in part supported by lactate provided by the CAFs, and anaplerosis [110] as shown in breast cancer cells [111] and others [112].
Welch, D.R.; Hurst, D.R. Defining the Hallmarks of Metastasis. Cancer Res. 2019, 79, 3011–3027. [CrossRef]
Mauffrey, P.; Tchitchek, N.; Barroca, V.; Bemelmans, A.; Firlej, V.; Allory, Y.; Roméo, P.-H.; Magnon, C. Progenitors from the central nervous system drive neurogenesis in cancer. Nature 2019, 569, 672–678. [CrossRef]
Haffner, M.C.; Zwart, W.; Roudier, M.P.; True, L.D.; Nelson, W.G.; Epstein, J.I.; De Marzo, A.M.; Nelson, P.S.; Yegnasubramanian, S. Genomic and phenotypic heterogeneity in prostate cancer. Nat. Rev. Urol. 2021, 18, 79–92. [CrossRef]
Jamal-Hanjani, M.; Wilson, G.A.; McGranahan, N.; Birkbak, N.J.; Watkins, T.B.K.; Veeriah, S.; Shafi, S.; Johnson, D.H.; Mitter, R.; Rosenthal, R.; et al. Tracking the Evolution of Non–Small-Cell Lung Cancer. Available online: https://www.nejm.org/doi/10.105 6/NEJMoa1616288 (accessed on 22 June 2021).
Russo, M.; Siravegna, G.; Blaszkowsky, L.S.; Corti, G.; Crisafulli, G.; Ahronian, L.G.; Mussolin, B.; Kwak, E.L.; Buscarino, M.; Lazzari, L.; et al. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 2016, 6, 147–153. [CrossRef]
O’Connor, J.P.B. Cancer heterogeneity and imaging. Semin. Cell Dev. Biol. 2017, 64, 48–57. [CrossRef]
McGranahan, N.; Swanton, C. Cancer Evolution Constrained by the Immune Microenvironment. Cell 2017, 170, 825–827. [CrossRef]
Suvà, M.L.; Tirosh, I. Single-Cell RNA Sequencing in Cancer: Lessons Learned and Emerging Challenges. Mol. Cell 2019, 75, 7–12. [CrossRef] [PubMed]
Baez-Ortega, A.; Gori, K.; Strakova, A.; Allen, J.L.; Allum, K.M.; Bansse-Issa, L.; Bhutia, T.N.; Bisson, J.L.; Briceño, C.; Domracheva, A.C.; et al. Somatic evolution and global expansion of an ancient transmissible cancer lineage. Science 2019, 365, eaau9923. [CrossRef] [PubMed]
Stammnitz, M.R.; Coorens, T.H.H.; Gori, K.C.; Hayes, D.; Fu, B.; Wang, J.; Martin-Herranz, D.E.; Alexandrov, L.B.; Baez-Ortega, A.; Barthorpe, S.; et al. The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils. Cancer Cell 2018, 33, 607–619.e15. [CrossRef] [PubMed]
Bullman, S.; Zou, T.; Meyerson, M. Mechanistic Insights into Transmissible Cancers of Mammals. Cancer Cell 2018, 33, 543–544. [CrossRef] [PubMed]
Pellacani, D.; Tan, S.; Lefort, S.; Eaves, C.J. Transcriptional regulation of normal human mammary cell heterogeneity and its perturbation in breast cancer. EMBO J. 2019, 38, e100330. [CrossRef]
Chmielik, E.; Rusinek, D.; Oczko-Wojciechowska, M.; Jarzab, M.; Krajewska, J.; Czarniecka, A.; Jarzab, B. Heterogeneity of Thyroid Cancer. Pathobiol. J. Immunopathol. Mol. Cell. Biol. 2018, 85, 117–129. [CrossRef]
González-Silva, L.; Quevedo, L.; Varela, I. Tumor Functional Heterogeneity Unraveled by scRNA-seq Technologies. Available online: https://www.cell.com/trends/cancer/fulltext/S2405-8033(19)30258-4 (accessed on 22 June 2021).
Dawson, M.A. The cancer epigenome: Concepts, challenges, and therapeutic opportunities. Science 2017, 355, 1147–1152. [CrossRef]
Guo, M.; Peng, Y.; Gao, A.; Du, C.; Herman, J.G. Epigenetic heterogeneity in cancer. Biomark. Res. 2019, 7, 23. [CrossRef] [PubMed]
Zhu, X.; Cheng, S. Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer. Endocrinol. Metab. 2017, 32, 326–331. [CrossRef] [PubMed]
Bateman, N.W.; Conrads, T.P. Recent advances and opportunities in proteomic analyses of tumour heterogeneity. J. Pathol. 2018, 244, 628–637. [CrossRef]
Frezza, C. Metabolism and cancer: The future is now. Br. J. Cancer 2020, 122, 133–135. [CrossRef] [PubMed]
Wen, S.-S.; Zhang, T.-T.; Xue, D.-X.; Wu, W.-L.; Wang, Y.-L.; Wang, Y.; Ji, Q.-H.; Zhu, Y.-X.; Qu, N.; Shi, R.-L. Metabolic reprogramming and its clinical application in thyroid cancer. Oncol. Lett. 2019, 18, 1579–1584. [CrossRef]
Baghban, R.; Roshangar, L.; Jahanban-Esfahlan, R.; Seidi, K.; Ebrahimi-Kalan, A.; Jaymand, M.; Kolahian, S.; Javaheri, T.; Zare, P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020, 18, 59. [CrossRef]
Yuan, Y. Spatial Heterogeneity in the Tumor Microenvironment. Cold Spring Harb. Perspect. Med. 2016, 6, a026583. [CrossRef]
Curtius, K.; Wright, N.A.; Graham, T.A. An evolutionary perspective on field cancerization. Nat. Rev. Cancer 2018, 18, 19–32. [CrossRef]
Gottlieb, B.; Trifiro, M.; Batist, G. Why Tumor Genetic Heterogeneity May Require Rethinking Cancer Genesis and Treatment. Trends Cancer 2021, 7, 400–409. [CrossRef]
Gawin, M.; Kurczyk, A.; Stobiecka, E.; Fratczak,˛ K.; Polańska, J.; Pietrowska, M.; Widłak, P. Molecular Heterogeneity of Papillary Thyroid Cancer: Comparison of Primary Tumors and Synchronous Metastases in Regional Lymph Nodes by Mass Spectrometry Imaging. Endocr. Pathol. 2019, 30, 250–261. [CrossRef] [PubMed]
Yin, X.; Jing, Y.; Cai, M.-C.; Ma, P.; Zhang, Y.; Xu, C.; Zhang, M.; Di, W.; Zhuang, G. Clonality, Heterogeneity, and Evolution of Synchronous Bilateral Ovarian Cancer. Cancer Res. 2017, 77, 6551–6561. [CrossRef]
Ciccarelli, F.D. Mutations differ in normal and cancer cells of the oesophagus. Nature 2019, 565, 301–303. [CrossRef]
Yokoyama, A.; Kakiuchi, N.; Yoshizato, T.; Nannya, Y.; Suzuki, H.; Takeuchi, Y.; Shiozawa, Y.; Sato, Y.; Aoki, K.; Kim, S.K.; et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 2019, 565, 312–317. [CrossRef] [PubMed]
Lloyd, M.C.; Cunningham, J.J.; Bui, M.M.; Gillies, R.J.; Brown, J.S.; Gatenby, R.A. Darwinian Dynamics of Intratumoral Heterogeneity: Not Solely Random Mutations but Also Variable Environmental Selection Forces. Cancer Res. 2016, 76, 3136–3144. [CrossRef] [PubMed]
Fernández, L.C.; Torres, M.; Real, F.X. Somatic mosaicism: On the road to cancer. Nat. Rev. Cancer 2016, 16, 43–55. [CrossRef]
Davis, A.; Gao, R.; Navin, N. Tumor evolution: Linear, branching, neutral or punctuated? Biochim. Biophys. Acta 2017, 1867, 151–161. [CrossRef]
Galofré, C.; Gönül Geyik, Ö.; Asensio, E.; Wangsa, D.; Hirsch, D.; Parra, C.; Saez, J.; Mollà, M.; Yüce, Z.; Castells, A.; et al. Tetraploidy-Associated Genetic Heterogeneity Confers Chemo-Radiotherapy Resistance to Colorectal Cancer Cells. Cancers 2020, 12, E1118. [CrossRef]
Herrera, E.L.; Azzam, S.Z.; Berger, M.C.; Diaz-Martinez, L.A. Genomic heterogeneity meets cellular energetics: Crosstalk between the mitochondria and the cell cycle. J. Cancer Metastasis Treat. 2018, 4, 42. [CrossRef]
Martincorena, I.; Raine, K.M.; Gerstung, M.; Dawson, K.J.; Haase, K.; Van Loo, P.; Davies, H.; Stratton, M.R.; Campbell, P.J. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell 2017, 171, 1029–1041.e21. [CrossRef]
Kumar, S.; Warrell, J.; Li, S.; McGillivray, P.D.; Meyerson, W.; Salichos, L.; Harmanci, A.; Martinez-Fundichely, A.; Chan, C.W.Y.; Nielsen, M.M.; et al. Passenger mutations in 2500 cancer genomes: Overall molecular functional impact and consequences. Cell 2020, 180, 915–927. [CrossRef] [PubMed]
Iranzo, J.; Martincorena, I.; Koonin, E.V. Cancer-mutation network and the number and specificity of driver mutations. Proc. Natl. Acad. Sci. USA 2018, 115, E6010–E6019. [CrossRef] [PubMed]
Koch, L. Cancer genomics: The driving force of cancer evolution. Nat. Rev. Genet. 2017, 18, 703. [CrossRef]
Zhao, Z.-M.; Zhao, B.; Bai, Y.; Iamarino, A.; Gaffney, S.G.; Schlessinger, J.; Lifton, R.P.; Rimm, D.L.; Townsend, J.P. Early and multiple origins of metastatic lineages within primary tumors. Proc. Natl. Acad. Sci. USA 2016, 113, 2140–2145. [CrossRef]
Townsend, J.P. Evolution Research Could Revolutionize Cancer Therapy. Scientific American, 18 April 2018. 18 April.
Hata, A.N.; Niederst, M.J.; Archibald, H.L.; Gomez-Caraballo, M.; Siddiqui, F.M.; Mulvey, H.E.; Maruvka, Y.E.; Ji, F.; Bhang, H.C.; Krishnamurthy Radhakrishna, V.; et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 2016, 22, 262–269. [CrossRef] [PubMed]
Schmitt, M.W.; Loeb, L.A.; Salk, J.J. The influence of subclonal resistance mutations on targeted cancer therapy. Nat. Rev. Clin. Oncol. 2016, 13, 335–347. [CrossRef] [PubMed]
Hoadley, K.A.; Siegel, M.B.; Kanchi, K.L.; Miller, C.A.; Ding, L.; Zhao, W.; He, X.; Parker, J.S.; Wendl, M.C.; Fulton, R.S.; et al. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. PLoS Med. 2016, 13, e1002174. [CrossRef]
Ulintz, P.J.; Greenson, J.K.; Wu, R.; Fearson, E.R.; Hardiman, K.M. Lymph Node Metastases in Colon Cancer Are Polyclonal. Available online: https://clincancerres.aacrjournals.org/content/24/9/2214.full (accessed on 7 June 2021).
Yuan, Y.; Ju, Y.S.; Kim, Y.; Li, J.; Wang, Y.; Yoon, C.J.; Yang, Y.; Martincorena, I.; Creighton, C.J.; Weinstein, J.N.; et al. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat. Genet. 2020, 52, 342–352. [CrossRef]
Assenov, Y.; Brocks, D.; Gerhäuser, C. Intratumor heterogeneity in epigenetic patterns. Semin. Cancer Biol. 2018, 51, 12–21. [CrossRef] [PubMed]
Feinberg, A.P. The Key Role of Epigenetics in Human Disease Prevention and Mitigation. N. Engl. J. Med. 2018, 378, 1323–1334. [CrossRef]
McGranahan, N.; Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017, 168, 613–628. [CrossRef]
Chung, W.; Eum, H.H.; Lee, H.-O.; Lee, K.-M.; Lee, H.-B.; Kim, K.-T.; Ryu, H.S.; Kim, S.; Lee, J.E.; Park, Y.H.; et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun. 2017, 8, 15081. [CrossRef]
Miyamoto, D.T.; Ting, D.T.; Toner, M.; Maheswaran, S.; Haber, D.A. Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. Cold Spring Harb. Symp. Quant. Biol. 2016, 81, 269–274. [CrossRef]
Sarkar, S.; Sabhachandani, P.; Ravi, D.; Potdar, S.; Purvey, S.; Beheshti, A.; Evens, A.M.; Konry, T. Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma. Front. Immunol. 2017, 8, 1736. [CrossRef]
Dominiak, A.; Chełstowska, B.; Olejarz, W.; Nowicka, G. Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions. Cancers 2020, 12, 1232. [CrossRef] [PubMed]
Najafi, M.; Goradel, N.H.; Farhood, B.; Salehi, E.; Solhjoo, S.; Toolee, H.; Kharazinejad, E.; Mortezaee, K. Tumor microenvironment: Interactions and therapy. J. Cell. Physiol. 2019, 234, 5700–5721. [CrossRef]
Houthuijzen, J.M.; Jonkers, J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. Cancer Metastasis Rev. 2018, 37, 577–597. [CrossRef]
Erdogan, B.; Ao, M.; White, L.M.; Means, A.L.; Brewer, B.M.; Yang, L.; Washington, M.K.; Shi, C.; Franco, O.E.; Weaver, A.M.; et al. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J. Cell Biol. 2017, 216, 3799–3816. [CrossRef]
Strickaert, A.; Corbet, C.; Spinette, S.-A.; Craciun, L.; Dom, G.; Andry, G.; Larsimont, D.; Wattiez, R.; Dumont, J.E.; Feron, O.; et al. Reprogramming of Energy Metabolism: Increased Expression and Roles of Pyruvate Carboxylase in Papillary Thyroid Cancer. Thyroid Off. J. Am. Thyroid Assoc. 2019, 29, 845–857. [CrossRef] [PubMed]
Zhang, W.; Bouchard, G.; Yu, A.; Shafiq, M.; Jamali, M.; Shrager, J.B.; Ayers, K.; Bakr, S.; Gentles, A.J.; Diehn, M.; et al. GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. Cancer Res. 2018, 78, 3445–3457. [CrossRef] [PubMed]
Farhood, B.; Najafi, M.; Mortezaee, K. Cancer-associated fibroblasts: Secretions, interactions, and therapy. J. Cell. Biochem. 2019, 120, 2791–2800. [CrossRef] [PubMed]
Lopes-Coelho, F.; André, S.; Félix, A.; Serpa, J. Breast cancer metabolic cross-talk: Fibroblasts are hubs and breast cancer cells are gatherers of lipids. Mol. Cell. Endocrinol. 2018, 462, 93–106. [CrossRef] [PubMed]
Dauer, P.; Zhao, X.; Gupta, V.K.; Sharma, N.; Kesh, K.; Gnamlin, P.; Dudeja, V.; Vickers, S.M.; Banerjee, S.; Saluja, A. Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Cancer Res. 2018, 78, 1321–1333. [CrossRef] [PubMed]
Öhlund, D.; Handly-Santana, A.; Biffi, G.; Elyada, E.; Almeida, A.S.; Ponz-Sarvise, M.; Corbo, V.; Oni, T.E.; Hearn, S.A.; Lee, E.J.; et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 2017, 214, 579–596. [CrossRef]
Mazzone, M.; Menga, A.; Castegna, A. Metabolism and TAM functions-it takes two to tango. FEBS J. 2018, 285, 700–716. [CrossRef]
Costa, A.; Kieffer, Y.; Scholer-Dahirel, A.; Pelon, F.; Bourachot, B.; Cardon, M.; Sirven, P.; Magagna, I.; Fuhrmann, L.; Bernard, C.; et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell 2018, 33, 463–479. [CrossRef]
Binnewies, M.; Roberts, E.W.; Kersten, K.; Chan, V.; Fearon, D.F.; Merad, M.; Coussens, L.M.; Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Hedrick, C.C.; et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018, 24, 541–550. [CrossRef]
Greten, F.R.; Grivennikov, S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 2019, 51, 27–41. [CrossRef] [PubMed]
O’Donnell, J.S.; Teng, M.W.L.; Smyth, M.J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019, 16, 151–167. [CrossRef]
Muenst, S.; Läubli, H.; Soysal, S.D.; Zippelius, A.; Tzankov, A.; Hoeller, S. The immune system and cancer evasion strategies: Therapeutic concepts. J. Intern. Med. 2016, 279, 541–562. [CrossRef] [PubMed]
Ulisse, S.; Tuccilli, C.; Sorrenti, S.; Antonelli, A.; Fallahi, P.; D’Armiento, E.; Catania, A.; Tartaglia, F.; Amabile, M.I.; Giacomelli, L.; et al. PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. Int. J. Mol. Sci. 2019, 20, 1405. [CrossRef]
Shrihari, T. Dual role of inflammatory mediators in cancer. Ecancermedicalscience 2017, 11, 721. [CrossRef]
Sulciner, M.L.; Serhan, C.N.; Gilligan, M.M.; Mudge, D.K.; Chang, J.; Gartung, A.; Lehner, K.A.; Bielenberg, D.R.; Schmidt, B.; Dalli, J.; et al. Resolvins suppress tumor growth and enhance cancer therapy. J. Exp. Med. 2018, 215, 115–140. [CrossRef]
Ferrari, S.M.; Fallahi, P.; Galdiero, M.R.; Ruffilli, I.; Elia, G.; Ragusa, F.; Paparo, S.R.; Patrizio, A.; Mazzi, V.; Varricchi, G.; et al. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int. J. Mol. Sci. 2019, 20, 4413. [CrossRef]
Ridker, P.M.; MacFadyen, J.G.; Thuren, T.; Everett, B.M.; Libby, P.; Glynn, R.J. CANTOS Trial Group Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet Lond. Engl. 2017, 390, 1833–1842. [CrossRef]
Long, A.G.; Lundsmith, E.T.; Hamilton, K.E. Inflammation and Colorectal Cancer. Curr. Colorectal Cancer Rep. 2017, 13, 341–351. [CrossRef] [PubMed]
Varricchi, G.; Loffredo, S.; Marone, G.; Modestino, L.; Fallahi, P.; Ferrari, S.M.; de Paulis, A.; Antonelli, A.; Galdiero, M.R. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. Int. J. Mol. Sci. 2019, 20, 3934. [CrossRef] [PubMed]
Puram, S.V.; Tirosh, I.; Parikh, A.S.; Patel, A.P.; Yizhak, K.; Gillespie, S.; Rodman, C.; Luo, C.L.; Mroz, E.A.; Emerick, K.S.; et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell 2017, 171, 1611–1624.e24. [CrossRef]
Spinelli, J.B.; Yoon, H.; Ringel, A.E.; Jeanfavre, S.; Clish, C.B.; Haigis, M.C. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science 2017, 358, 941–946. [CrossRef]
Jung, J.G.; Le, A. Targeting Metabolic Cross Talk Between Cancer Cells and Cancer-Associated Fibroblasts. Adv. Exp. Med. Biol. 2021, 1311, 205–214. [CrossRef]
Murray, P.J. Nonresolving macrophage-mediated inflammation in malignancy. FEBS J. 2018, 285, 641–653. [CrossRef]
Schmidt, E.M.; Lamprecht, S.; Blaj, C.; Schaaf, C.; Krebs, S.; Blum, H.; Hermeking, H.; Jung, A.; Kirchner, T.; Horst, D. Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer. J. Exp. Med. 2018, 215, 1693–1708. [CrossRef] [PubMed]
Chen, X.; Mims, J.; Huang, X.; Singh, N.; Motea, E.; Planchon, S.M.; Beg, M.; Tsang, A.W.; Porosnicu, M.; Kemp, M.L.; et al. Modulators of Redox Metabolism in Head and Neck Cancer. Antioxid. Redox Signal. 2018, 29, 1660–1690. [CrossRef] [PubMed]
Dovmark, T.H.; Hulikova, A.; Niederer, S.A.; Vaughan-Jones, R.D.; Swietach, P. Normoxic cells remotely regulate the acid-base balance of cells at the hypoxic core of connexin-coupled tumor growths. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2018, 32, 83–96. [CrossRef] [PubMed]
Bullman, S.; Pedamallu, C.S.; Sicinska, E.; Clancy, T.E.; Zhang, X.; Cai, D.; Neuberg, D.; Huang, K.; Guevara, F.; Nelson, T.; et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017, 358, 1443–1448. [CrossRef]
Michiels, C.; Tellier, C.; Feron, O. Cycling hypoxia: A key feature of the tumor microenvironment. Biochim. Biophys. Acta Rev. Cancer 2016, 1866, 76–86. [CrossRef]
Xie, H.; Simon, M.C. Oxygen availability and metabolic reprogramming in cancer. J. Biol. Chem. 2017, 292, 16825–16832. [CrossRef]
Heiland, D.H.; Gaebelein, A.; Börries, M.; Wörner, J.; Pompe, N.; Franco, P.; Heynckes, S.; Bartholomae, M.; hAilín, D.Ó.; Carro, M.S.; et al. Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme. Mol. Cancer Res. MCR 2018, 16, 655–668. [CrossRef]
Assi, M. The differential role of reactive oxygen species in early and late stages of cancer. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2017, 313, R646–R653. [CrossRef]
Corbet, C.; Feron, O. Tumour acidosis: From the passenger to the driver’s seat. Nat. Rev. Cancer 2017, 17, 577–593. [CrossRef] [PubMed]
Neveu, M.-A.; De Preter, G.; Marchand, V.; Bol, A.; Brender, J.R.; Saito, K.; Kishimoto, S.; Porporato, P.E.; Sonveaux, P.; Grégoire, V.; et al. Multimodality Imaging Identifies Distinct Metabolic Profiles In Vitro and In Vivo. Neoplasia 2016, 18, 742–752. [CrossRef]
Pillai, S.R.; Damaghi, M.; Marunaka, Y.; Spugnini, E.P.; Fais, S.; Gillies, R.J. Causes, Consequences, and Therapy of Tumors Acidosis. Cancer Metastasis Rev. 2019, 38, 205–222. [CrossRef] [PubMed]
Corbet, C.; Feron, O. Cancer cell metabolism and mitochondria: Nutrient plasticity for TCA cycle fueling. Biochim. Biophys. Acta Rev. Cancer 2017, 1868, 7–15. [CrossRef] [PubMed]
Corbet, C.; Pinto, A.; Martherus, R.; Santiago de Jesus, J.P.; Polet, F.; Feron, O. Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation. Cell Metab. 2016, 24, 311–323. [CrossRef] [PubMed]
Hensley, C.T.; Faubert, B.; Yuan, Q.; Lev-Cohain, N.; Jin, E.; Kim, J.; Jiang, L.; Ko, B.; Skelton, R.; Loudat, L.; et al. Metabolic Heterogeneity in Human Lung Tumors. Cell 2016, 164, 681–694. [CrossRef]
Roswall, P.; Bocci, M.; Bartoschek, M.; Li, H.; Kristiansen, G.; Jansson, S.; Lehn, S.; Sjölund, J.; Reid, S.; Larsson, C.; et al. Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. Nat. Med. 2018, 24, 463–473. [CrossRef] [PubMed]
McQuerry, J.A.; Chang, J.T.; Bowtell, D.D.L.; Cohen, A.; Bild, A.H. Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. J. Mol. Med. 2017, 95, 1167–1178. [CrossRef] [PubMed]
Fugazzola, L.; Muzza, M.; Pogliaghi, G.; Vitale, M. Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance. Cancers 2020, 12, 383. [CrossRef]
MacDonald, L.; Jenkins, J.; Purvis, G.; Lee, J.; Franco, A.T. The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication. Horm. Cancer 2020, 11, 205–217. [CrossRef]
Ameziane El Hassani, R.; Buffet, C.; Leboulleux, S.; Dupuy, C. Oxidative stress in thyroid carcinomas: Biological and clinical significance. Endocr. Relat. Cancer 2019, 26, R131–R143. [CrossRef]
Prete, A.; Borges de Souza, P.; Censi, S.; Muzza, M.; Nucci, N.; Sponziello, M. Update on Fundamental Mechanisms of Thyroid Cancer. Front. Endocrinol. 2020, 11, 102. [CrossRef]
Zaballos, M.A.; Santisteban, P. Key signaling pathways in thyroid cancer. J. Endocrinol. 2017, 235, R43–R61. [CrossRef]
Tuccilli, C.; Baldini, E.; Sorrenti, S.; Catania, A.; Antonelli, A.; Fallahi, P.; Tartaglia, F.; Barollo, S.; Mian, C.; Palmieri, A.; et al. CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. Available online: https://www.hindawi.com/journals/ije/2018/1742951/abs/(accessed on 12 July 2019).
Masoodi, T.; Siraj, A.K.; Siraj, S.; Azam, S.; Qadri, Z.; Parvathareddy, S.K.; Al-Sobhi, S.S.; AlDawish, M.; Alkuraya, F.S.; Al-Kuraya, K.S. Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer. Am. J. Hum. Genet. 2019, 105, 959–973. [CrossRef]
Yang, J.; Ma, Y.; Gong, Y.; Gong, R.; Li, Z.; Zhu, J. Multiple Simultaneous Rare Distant Metastases as the Initial Presentation of Papillary Thyroid Carcinoma: A Case Report. Front. Endocrinol. 2019, 10, 759. [CrossRef] [PubMed]
Kakudo, K.; Liu, Z.; Bychkov, A.; Jung, C.K. Nuclear Features of Papillary Thyroid Carcinoma (BRAF-like Tumors), Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (RAS-like Tumors), and Follicular Adenoma/Follicular Thyroid Carcinoma (RAS-Like Tumors); Springer: Singapore, 2019; pp. 173–179. ISBN 9789811318962.
Tarabichi, M.; Antoniou, A.; Le Pennec, S.; Gacquer, D.; de Saint Aubain, N.; Craciun, L.; Cielen, T.; Laios, I.; Larsimont, D.; Andry, G.; et al. Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers. J. Clin. Endocrinol. Metab. 2018, 103, 1102–1111. [CrossRef]
Jolly, L.A.; Novitskiy, S.; Owens, P.; Massoll, N.; Cheng, N.; Fang, W.; Moses, H.L.; Franco, A.T. Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by BrafV600E and Pten loss. Cancer Res. 2016, 76, 1804–1813. [CrossRef] [PubMed]
Strickaert, A.; Saiselet, M.; Dom, G.; De Deken, X.; Dumont, J.E.; Feron, O.; Sonveaux, P.; Maenhaut, C. Cancer heterogeneity is not compatible with one unique cancer cell metabolic map. Oncogene 2017, 36, 2637–2642. [CrossRef]
Pasanen, I.; Lehtonen, S.; Sormunen, R.; Skarp, S.; Lehtilahti, E.; Pietilä, M.; Sequeiros, R.B.; Lehenkari, P.; Kuvaja, P. Breast cancer carcinoma-associated fibroblasts differ from breast fibroblasts in immunological and extracellular matrix regulating pathways. Exp. Cell Res. 2016, 344, 53–66. [CrossRef]
Icard, P.; Lincet, H. A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells. Biochim. Biophys. Acta 2012, 1826, 423–433. [CrossRef] [PubMed]
Dom, G.; Frank, S.; Floor, S.; Kehagias, P.; Libert, F.; Hoang, C.; Andry, G.; Spinette, A.; Craciun, L.; de Saint Aubin, N.; et al. Thyroid follicular adenomas and carcinomas: Molecular profiling provides evidence for a continuous evolution. Oncotarget 2017, 9, 10343–10359. [CrossRef]
Parameswaran, R.; Shulin Hu, J.; Min En, N.; Tan, W.; Yuan, N. Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation. Ann. R. Coll. Surg. Engl. 2017, 99, 151–154. [CrossRef]
Molinaro, E.; Romei, C.; Biagini, A.; Sabini, E.; Agate, L.; Mazzeo, S.; Materazzi, G.; Sellari-Franceschini, S.; Ribechini, A.; Torregrossa, L.; et al. Anaplastic thyroid carcinoma: From clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 2017, 13, 644–660. [CrossRef]
Takano, T.; Amino, N. Fetal cell carcinogenesis: A new hypothesis for better understanding of thyroid carcinoma. Thyroid Off. J. Am. Thyroid Assoc. 2005, 15, 432–438. [CrossRef]
Gianì, F.; Vella, V.; Tumino, D.; Malandrino, P.; Frasca, F. The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer. Cancers 2020, 12, 2249. [CrossRef]
Hébrant, A.; Dom, G.; Dewaele, M.; Andry, G.; Trésallet, C.; Leteurtre, E.; Dumont, J.E.; Maenhaut, C. mRNA Expression in Papillary and Anaplastic Thyroid Carcinoma: Molecular Anatomy of a Killing Switch. PLoS ONE 2012, 7, e37807. [CrossRef]
Landa, I.; Ibrahimpasic, T.; Boucai, L.; Sinha, R.; Knauf, J.A.; Shah, R.H.; Dogan, S.; Ricarte-Filho, J.C.; Krishnamoorthy, G.P.; Xu, B.; et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Investig. 2016, 126, 1052–1066. [CrossRef]
Menicali, E.; Guzzetti, M.; Morelli, S.; Moretti, S.; Puxeddu, E. Immune Landscape of Thyroid Cancers: New Insights. Front. Endocrinol. 2021, 11, 7826. [CrossRef]
Fozzatti, L.; Alamino, V.A.; Park, S.; Giusiano, L.; Volpini, X.; Zhao, L.; Stempin, C.C.; Donadio, A.C.; Cheng, S.; Pellizas, C.G. Interplay of fibroblasts with anaplastic tumor cells promotes follicular thyroid cancer progression. Sci. Rep. 2019, 9, 8028. [CrossRef] [PubMed]
Lan, L.; Luo, Y.; Zhou, M.; Huo, L.; Chen, H.; Zuo, Q.; Deng, W. Comparison of Diagnostic Accuracy of Thyroid Cancer With Ultrasound-Guided Fine-Needle Aspiration and Core-Needle Biopsy: A Systematic Review and Meta-Analysis. Front. Endocrinol. 2020, 11, 44. [CrossRef] [PubMed]
Tarabichi, M.; Demetter, P.; Craciun, L.; Maenhaut, C.; Detours, V. Thyroid cancer under the scope of emerging technologies. Mol. Cell. Endocrinol. 2022, 541, 111491. [CrossRef] [PubMed]
Naoum, G.E.; Morkos, M.; Kim, B.; Arafat, W. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol. Cancer 2018, 17, 51. [CrossRef]
Laha, D.; Nilubol, N.; Boufraqech, M. New Therapies for Advanced Thyroid Cancer. Front. Endocrinol. 2020, 11, 82. [CrossRef]
San Román Gil, M.; Pozas, J.; Molina-Cerrillo, J.; Gómez, J.; Pian, H.; Pozas, M.; Carrato, A.; Grande, E.; Alonso-Gordoa, T. Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. Int. J. Mol. Sci. 2020, 21, 4951. [CrossRef]
Sugishita, Y.; Kammori, M.; Yamada, O.; Poon, S.S.S.; Kobayashi, M.; Onoda, N.; Yamazaki, K.; Fukumori, T.; Yoshikawa, K.-I.; Onose, H.; et al. Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening. Int. J. Oncol. 2013, 42, 1589–1596. [CrossRef]
Ensinger, C.; Prommegger, R.; Kendler, D.; Gabriel, M.; Spizzo, G.; Mikuz, G.; Kremser, R. Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas. Anticancer Res. 2003, 23, 2349–2353.
Wei, W.; Jiang, D.; Rosenkrans, Z.T.; Barnhart, T.E.; Engle, J.W.; Luo, Q.; Cai, W. HER2-targeted multimodal imaging of anaplastic thyroid cancer. Am. J. Cancer Res. 2019, 9, 2413–2427. [PubMed]
Ruggeri, R.M.; Campennì, A.; Giuffrè, G.; Giovanella, L.; Siracusa, M.; Simone, A.; Branca, G.; Scarfì, R.; Trimarchi, F.; Ieni, A.; et al. HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin. Int. J. Mol. Sci. 2016, 17, 2040. [CrossRef]
Buffet, C.; Wassermann, J.; Hecht, F.; Leenhardt, L.; Dupuy, C.; Groussin, L.; Lussey-Lepoutre, C. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr. Relat. Cancer 2020, 27, R113–R132. [CrossRef] [PubMed]
Coudray, N.; Ocampo, P.S.; Sakellaropoulos, T.; Narula, N.; Snuderl, M.; Fenyö, D.; Moreira, A.L.; Razavian, N.; Tsirigos, A. Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat. Med. 2018, 24, 1559–1567. [CrossRef] [PubMed]
Chervoneva, I.; Peck, A.R.; Yi, M.; Freydin, B.; Rui, H. Quantification of spatial tumor heterogeneity in immunohistochemistry staining images. Bioinformatics 2021, 37, 1452–1460. [CrossRef]
Bonin, S.; Stanta, G. Pre-analytics and tumor heterogeneity. New Biotechnol. 2020, 55, 30–35. [CrossRef]
Russano, M.; Napolitano, A.; Ribelli, G.; Iuliani, M.; Simonetti, S.; Citarella, F.; Pantano, F.; Dell’Aquila, E.; Anesi, C.; Silvestris, N.; et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples. J. Exp. Clin. Cancer Res. 2020, 39, 95. [CrossRef] [PubMed]
Ståhl, P.L.; Salmén, F.; Vickovic, S.; Lundmark, A.; Navarro, J.F.; Magnusson, J.; Giacomello, S.; Asp, M.; Westholm, J.O.; Huss, M.; et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science 2016, 353, 78–82. [CrossRef] [PubMed]
Saiselet, M.; Rodrigues-Vitória, J.; Tourneur, A.; Craciun, L.; Spinette, A.; Larsimont, D.; Andry, G.; Lundeberg, J.; Maenhaut, C.; Detours, V. Transcriptional output, cell-type densities, and normalization in spatial transcriptomics. J. Mol. Cell Biol. 2020, 12, 906–908. [CrossRef] [PubMed]
Longo, S.K.; Guo, M.G.; Ji, A.L.; Khavari, P.A. Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. Nat. Rev. Genet. 2021, 22, 627–644. [CrossRef] [PubMed]
Fan, H.; Demirci, U.; Chen, P. Emerging organoid models: Leaping forward in cancer research. J. Hematol. Oncol. 2019, 12, 142. [CrossRef]
Porter, R.J.; Murray, G.I.; McLean, M.H. Current concepts in tumour-derived organoids. Br. J. Cancer 2020, 123, 1209–1218. [CrossRef]
Yang, C.; Xia, B.-R.; Jin, W.-L.; Lou, G. Circulating tumor cells in precision oncology: Clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int. 2019, 19, 341. [CrossRef]
Treglia, G.; Annunziata, S.; Muoio, B.; Salvatori, M.; Ceriani, L.; Giovanella, L. The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Aggressive Histological Subtypes of Thyroid Cancer: An Overview. Int. J. Endocrinol. 2013, 2013, 856189. [CrossRef]
Shen, K.; Liu, B.; Zhou, X.; Ji, Y.; Chen, L.; Wang, Q.; Xue, W. The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer. Front. Oncol. 2021, 11, 2436. [CrossRef]
Larg, M.I.; Barbus, E.; Gabora, K.; Pestean, C.; Cheptea, M.; Piciu, D. 18F-FDG PET/CT IN DIFFERENTIATED THYROID CARCINOMA. Acta Endocrinol. Buchar. 2019, 15, 203–208. [CrossRef]
Kaushik, A.K.; DeBerardinis, R.J. Applications of metabolomics to study cancer metabolism. Biochim. Biophys. Acta Rev. Cancer 2018, 1870, 2–14. [CrossRef]
Schmidt, D.R.; Patel, R.; Kirsch, D.G.; Lewis, C.A.; Heiden, M.G.V.; Locasale, J.W. Metabolomics in cancer research and emerging applications in clinical oncology. CA. Cancer J. Clin. 2021, 71, 333–358. [CrossRef] [PubMed]
van Manen, L.; Dijkstra, J.; Boccara, C.; Benoit, E.; Vahrmeijer, A.L.; Gora, M.J.; Mieog, J.S.D. The clinical usefulness of optical coherence tomography during cancer interventions. J. Cancer Res. Clin. Oncol. 2018, 144, 1967–1990. [CrossRef] [PubMed]
Nakamura, K.; Aimono, E.; Tanishima, S.; Imai, M.; Nagatsuma, A.K.; Hayashi, H.; Yoshimura, Y.; Nakayama, K.; Kyo, S.; Nishihara, H. Intratumoral Genomic Heterogeneity May Hinder Precision Medicine Strategies in Patients with Serous Ovarian Carcinoma. Diagnostics 2020, 10, 200. [CrossRef]
Raspollini, M.R.; Montagnani, I.; Montironi, R.; Castiglione, F.; Martignoni, G.; Cheng, L.; Lopez-Beltran, A. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. J. Clin. Pathol. 2018, 71, 467–471. [CrossRef]
Hoffman, M.; Gillmor, A.H.; Kunz, D.J.; Johnston, M.J.; Nikolic, A.; Narta, K.; Zarrei, M.; King, J.; Ellestad, K.; Dang, N.H.; et al. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Res. 2019, 79, 2111–2123. [CrossRef] [PubMed]
Hunter, K.W.; Amin, R.; Deasy, S.; Ha, N.-H.; Wakefield, L. Genetic insights into the morass of metastatic heterogeneity. Nat. Rev. Cancer 2018, 18, 211–223. [CrossRef]
Hyman, D.M.; Piha-Paul, S.A.; Won, H.; Rodon, J.; Saura, C.; Shapiro, G.I.; Juric, D.; Quinn, D.I.; Moreno, V.; Doger, B.; et al. HER kinase inhibition in patients with HER2-and HER3-mutant cancers. Nature 2018, 554, 189–194. [CrossRef]
Gambardella, V.; Fleitas, T.; Tarazona, N.; Cejalvo, J.M.; Gimeno-Valiente, F.; Martinez-Ciarpaglini, C.; Huerta, M.; Roselló, S.; Castillo, J.; Roda, D.; et al. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. Ann. Oncol. 2019, 30, 1254–1264. [CrossRef]
Sheng, S.; Margarida Bernardo, M.; Dzinic, S.H.; Chen, K.; Heath, E.I.; Sakr, W.A. Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: Our experience and a literature review. Cancer Metastasis Rev. 2018, 37, 655–663. [CrossRef]
Baliu-Piqué, M.; Pandiella, A.; Ocana, A. Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers 2020, 12, 3271. [CrossRef]
Gerlinger, M.; Rowan, A.J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883–892. [CrossRef] [PubMed]
Rios, A.C.; Capaldo, B.D.; Vaillant, F.; Pal, B.; van Ineveld, R.; Dawson, C.A.; Chen, Y.; Nolan, E.; Fu, N.Y.; Jackling, F.C.; et al. Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. Cancer Cell 2019, 35, 618–632.e6. [CrossRef] [PubMed]
Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature 2018, 553, 446–454. [CrossRef] [PubMed]
Tourneau, C.L.; Borcoman, E.; Kamal, M. Molecular profiling in precision medicine oncology. Nat. Med. 2019, 25, 711. [CrossRef]
Barok, M.; Puhka, M.; Vereb, G.; Szollosi, J.; Isola, J.; Joensuu, H. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer 2018, 18, 504. [CrossRef]
Wu, P.; Gao, W.; Su, M.; Nice, E.C.; Zhang, W.; Lin, J.; Xie, N. Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front. Cell Dev. Biol. 2021, 9, 641469. [CrossRef] [PubMed]
Guo, Q.; Wang, H.; Yan, Y.; Liu, Y.; Su, C.; Chen, H.; Yan, Y.; Adhikari, R.; Wu, Q.; Zhang, J. The Role of Exosomal microRNA in Cancer Drug Resistance. Front. Oncol. 2020, 10, 472. [CrossRef]
Coulie, P.G.; Van den Eynde, B.J.; van der Bruggen, P.; Boon, T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat. Rev. Cancer 2014, 14, 135–146. [CrossRef]
Mehnert, J.M.; Varga, A.; Brose, M.S.; Aggarwal, R.R.; Lin, C.-C.; Prawira, A.; de Braud, F.; Tamura, K.; Doi, T.; Piha-Paul, S.A.; et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 2019, 19, 196. [CrossRef]
Demaria, O.; Cornen, S.; Daëron, M.; Morel, Y.; Medzhitov, R.; Vivier, E. Harnessing innate immunity in cancer therapy. Nature 2019, 574, 45–56. [CrossRef] [PubMed]
Vitale, I.; Shema, E.; Loi, S.; Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 2021, 27, 212–224. [CrossRef] [PubMed]
Ott, P.A.; Hu, Z.; Keskin, D.B.; Shukla, S.A.; Sun, J.; Bozym, D.J.; Zhang, W.; Luoma, A.; Giobbie-Hurder, A.; Peter, L.; et al. An Immunogenic Personal Neoantigen Vaccine for Melanoma Patients. Nature 2017, 547, 217–221. [CrossRef] [PubMed]
Sahin, U.; Derhovanessian, E.; Miller, M.; Kloke, B.-P.; Simon, P.; Löwer, M.; Bukur, V.; Tadmor, A.D.; Luxemburger, U.; Schrörs, B.; et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017, 547, 222–226. [CrossRef] [PubMed]
Jiang, T.; Cheng, R.; Pan, Y.; Zhang, H.; He, Y.; Su, C.; Ren, S.; Zhou, C. Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer. Transl. Lung Cancer Res. 2020, 9, 246–256. [CrossRef]
Bernards, R. Finding effective cancer therapies through loss of function genetic screens. Curr. Opin. Genet. Dev. 2014, 24, 23–29. [CrossRef] [PubMed]
Wang, C.; Jin, H.; Gao, D.; Lieftink, C.; Evers, B.; Jin, G.; Xue, Z.; Wang, L.; Beijersbergen, R.L.; Qin, W.; et al. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J. Hepatol. 2018, 69, 1057–1065. [CrossRef]
